Hepatobiliary Cancer Coverage from Every Angle
Editor:
Al B. Benson III, MD, FACP, FASCO
Advertisement
Advertisement

Available Clinical Trials

A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma and Other Advanced Solid Tumors
A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma and Other Advanced Solid Tumors
A Phase I/II Study of Relatlimab in Combination With Nivolumab and Bevacizumab for People With Advanced Liver Cancer
A Phase IB/II Pressure-Enabled Regional Immuno-oncology Study of Hepatic Arterial Infusion of SD-101 With Systemic Checkpoint Blockade for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study of Multiple Immunotherapy-Based Treatment Combinations in Advanced Liver Cancers
A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
A Phase II, Multicenter, Clinical Study of MK 1308A in Combination With Lenvatinib in First-line Therapy for Advanced Hepatocellular Carcinoma
A Phase III Study of Durvalumab, Tremelimumab, and Transarterial Chemoembolization (TACE) Given With or Without Lenvatinib Compared to TACE Alone in People With Localized Liver Cancer
A Randomized Phase II Study of Systemic Chemotherapy With or Without HAI FUDR/Dexamethasone in Patients With Unresectable Intrahepatic Cholangiocarcinoma
A Study of Intratumoral Injection of Dendritic Cells After High-Dose Conformal External-Beam Radiotherapy in Patients With Unresectable Liver Cancer
Ablation vs Stereotactic Body Radiotherapy for Early-Stage Hepatocellular Carcinoma Not Amenable to Surgical Treatment
ALTUS: Performance of a Multitarget Hepatocellular Carcinoma Test in Subjects With Increased Risk
Atezolizumab in Combination With a Multikinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Circulating Biomarkers for Immunotherapy Resistance in Liver Cancer
Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment
Gadolinium Contrast-Enhanced Abbreviated MRI vs Standard Ultrasound for Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis
Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition
Impact of Mutation Profiling in Surgical Management for Cholangiocarcinoma
Is Chemotherapy, Bevazicumab, and Atezolizumab Better Than Chemotherapy Alone in Patients With Advanced Liver Cancer?
Liver Cancer Disparities in American Indian and Alaska Native Persons
NAPOLI-2: Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer
National Translational Science Network of Precision-Based Immunotherapy for Primary Liver Cancer
Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer (NAPOLI-2)
JNCCN360 Link Name Phase II Trial of Chemotherapy With or Without Hepatic Artery Infusion for Intrahepatic Cholangiocarcinoma
Software-Aided Imaging (Morfeus) for Confirming Tumor Coverage With Ablation in Patients With Liver Tumors, the COVER-ALL Study
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
Study to Evaluate the Efficacy and Safety of TT-00420 in Cholangiocarcinoma
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer
VG161 in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Copyright © 2023 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.